-
公开(公告)号：US20140134152A1
公开(公告)日：2014-05-15
申请号：US14116115
申请日：2012-05-04
IPC分类号： A61K38/48
CPC分类号： A61K38/4853 , A61K38/482
摘要： Embodiments of the present invention relate to compositions and methods of treating patients for type 1 diabetes mellitus (T1D) by administering a therapeutically effective dose of recombinant human KLK1, variants of KLK1, or active fragments thereof. Such patients may be increase risk patients for developing T1D or T1D patients in the Honeymoon Phase. Such treatment may be expected to prevent or delay the onset of T1D, to ameliorate the symptoms of T1D, or to ameliorate the extent to which the T1D manifests.
摘要翻译： 本发明的实施方案涉及通过施用治疗有效剂量的重组人KLK1，KLK1的变体或其活性片段来治疗1型糖尿病（T1D）患者的组合物和方法。 这些患者可能会增加患者在蜜月期发展T1D或T1D患者的风险。 预期这种治疗可以预防或延缓T1D的发作，改善T1D的症状，或改善T1D表现的程度。
-
公开(公告)号：US20110150781A1
公开(公告)日：2011-06-23
申请号：US13055660
申请日：2009-07-24
申请人： Matthew L. Charles , Mark Williams
发明人： Matthew L. Charles , Mark Williams
CPC分类号： A61K38/4853 , A61N1/36067 , C12Y304/21008
摘要： The invention relates to methods of treating Parkinson's disease, dementia with Lewy bodies, and conditions associated with Parkinson's disease and dementia with Lewy bodies. Methods include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof.
摘要翻译： 本发明涉及治疗帕金森病，路易体痴呆和与帕金森病和路易体痴呆相关的病症的方法。 方法包括施用治疗有效量的组织激肽释放酶，其变体或活性片段。
-
公开(公告)号：US20120276019A1
公开(公告)日：2012-11-01
申请号：US13494788
申请日：2012-06-12
CPC分类号： A61K9/0043 , A61K38/4853 , A61K45/06 , A61N1/36067 , A61K2300/00
摘要： Provided herein are methods of treating Parkinson's disease, dementia with Lewy bodies, and conditions associated with Parkinson's disease and dementia with Lewy bodies. These methods include administering to a subject in need thereof a therapeutically effective amount of a tissue kallikrein (KLK1) polypeptide, including active variants and fragments thereof.
摘要翻译： 本文提供了治疗帕金森病，路易体痴呆和与帕金森病和路易体痴呆相关的病症的方法。 这些方法包括向有需要的受试者施用治疗有效量的组织激肽释放酶（KLK1）多肽，包括其活性变体和片段。
-
-
搜索结果
3 条记录 (耗时 0.019 秒)
